146 related articles for article (PubMed ID: 14970855)
1. Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions.
Royston P; Sauerbrei W; Ritchie A
Br J Cancer; 2004 Feb; 90(4):794-9. PubMed ID: 14970855
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.
Lancet; 1999 Jan; 353(9146):14-7. PubMed ID: 10023944
[TBL] [Abstract][Full Text] [Related]
3. On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma. Urological Working Party Renal Carcinoma Subgroup.
Fayers PM; Cook PA; Machin D; Donaldson N; Whitehead J; Ritchie A; Oliver RT; Yuen P
Stat Med; 1994 Nov; 13(21):2249-60. PubMed ID: 7846423
[TBL] [Abstract][Full Text] [Related]
4. Modest effect of interferon alfa on metastatic renal-cell carcinoma.
Amato R
Lancet; 1999 Jan; 353(9146):6-7. PubMed ID: 10023941
[No Abstract] [Full Text] [Related]
5. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
Lee CP; Patel PM; Selby PJ; Hancock BW; Mak I; Pyle L; James MG; Beirne DA; Steeds S; A'Hern R; Gore ME; Eisen T
J Clin Oncol; 2006 Feb; 24(6):898-903. PubMed ID: 16484699
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.
Kawano Y; Takahashi W; Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S
Cancer Sci; 2016 Jul; 107(7):1013-7. PubMed ID: 27089226
[TBL] [Abstract][Full Text] [Related]
7. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study.
Pizzocaro G; Piva L; Colavita M; Ferri S; Artusi R; Boracchi P; Parmiani G; Marubini E
J Clin Oncol; 2001 Jan; 19(2):425-31. PubMed ID: 11208835
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.
Kankuri M; Pelliniemi TT; Pyrhönen S; Nikkanen V; Helenius H; Salminen E
Cancer; 2001 Aug; 92(4):761-7. PubMed ID: 11550145
[TBL] [Abstract][Full Text] [Related]
9. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
11. [High-dose medroxyprogesterone acetate in the treatment of metastatic carcinoma of renal parenchyma].
Popov I; Jelić S; Milanović N; Kovcin V; Vuletić Lj
Srp Arh Celok Lek; 1996; 124(3-4):73-6. PubMed ID: 9102823
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma.
Naglieri E; Lopez M; Lelli G; Morelli F; Amodio A; Di Tonno P; Gebbia N; Di Seri M; Chetri MC; Rizzo P; Abbate I; Casamassima A; Selvaggi FP; Colucci G
Anticancer Res; 2002; 22(5):3045-51. PubMed ID: 12530040
[TBL] [Abstract][Full Text] [Related]
13. [Renal carcinoma: effective modulation of low-dose interferon-alpha and interleukin-2 with medroxyprogesterone acetate and 13-cis retinoic acid].
Caponetti R; Amodio A; Naglieri E; Caponetti T; Crecco M; Lopez M
Clin Ter; 2000; 151(4):283-6. PubMed ID: 11107678
[TBL] [Abstract][Full Text] [Related]
14. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
[TBL] [Abstract][Full Text] [Related]
15. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.
Negrier S; Perol D; Ravaud A; Chevreau C; Bay JO; Delva R; Sevin E; Caty A; Escudier B;
Cancer; 2007 Dec; 110(11):2468-77. PubMed ID: 17932908
[TBL] [Abstract][Full Text] [Related]
16. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
Minasian LM; Motzer RJ; Gluck L; Mazumdar M; Vlamis V; Krown SE
J Clin Oncol; 1993 Jul; 11(7):1368-75. PubMed ID: 8315435
[TBL] [Abstract][Full Text] [Related]
17. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
Motzer RJ; Bacik J; Murphy BA; Russo P; Mazumdar M
J Clin Oncol; 2002 Jan; 20(1):289-96. PubMed ID: 11773181
[TBL] [Abstract][Full Text] [Related]
19. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon.
Ng CS; Wang X; Faria SC; Lin E; Charnsangavej C; Tannir NM
AJR Am J Roentgenol; 2010 Jan; 194(1):166-71. PubMed ID: 20028919
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
